Biodexa Pharmaceuticals (BDRX) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Biodexa Pharmaceuticals reports promising interim results in their Phase 1 study of MTX110 for treating recurrent glioblastoma, showing favorable overall survival rates compared to standard treatments. The data also builds on previous positive outcomes from two Phase 1 studies in diffuse midline glioma, indicating the potential of MTX110, which is delivered directly to the tumor, in treating aggressive brain cancers.
For further insights into BDRX stock, check out TipRanks’ Stock Analysis page.
